Ipsen ( OTCPK:IPSEY ) and Marengo Therapeutics announced the expansion of their ongoing oncology research partnership, to include TriSTAR, Marengo’s next-generation, precision T cell engager technology. Under the terms of the agreement, Ipsen will assume responsibility for all activities following development candidate nomination. Marengo will receive an upfront payment and potential payments up to a total of $1.
2 billion if all milestones are met in addition to tiered sales royalty payments. Source: Press Release More on Ipsen S.A.
Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors Ipsen S.A. reports Q1 results; reaffirms full-year guidance Ipsen, Skyhawk enter RNA targeting research collab in rare neurological diseases Historical earnings data for Ipsen S.
A. Dividend scorecard for Ipsen S.A.
.